At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Not Yet Opened 04-06 16:00:00 EDT
1.59
+0.00
0.00%
盘后1.59
+0.000.00%
19:49 EDT
High1.66Low1.55Vol181.45K
Open1.61D1 Closing1.59Amplitude6.60%
Mkt Cap22.81MTradable Cap14.74MTotal Shares14.34M
T/O290.71KT/O Rate1.96%Tradable Shares9.27M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Tempest Therapeutics Inc - Company Will Not Receive Proceeds From Sale of Shares by Selling Stockholders - SEC Filing
THOMSON REUTERS  ·  04-02
Tempest Therapeutics Inc - Company Will Not Receive Proceeds From Sale of Shares by Selling Stockholders - SEC Filing
Tempest Therapeutics Inc - Prospectus Filed for Resale of up to About 2.8 Mln Shares Including Warrants - SEC Filing
THOMSON REUTERS  ·  04-02
Tempest Therapeutics Inc - Prospectus Filed for Resale of up to About 2.8 Mln Shares Including Warrants - SEC Filing
Tempest Therapeutics files to sell 2.78M shares of common stock for holders
TIPRANKS  ·  04-02
Tempest Therapeutics files to sell 2.78M shares of common stock for holders
Tempest Therapeutics files to sell 8.27M shares of common stock for holders
TIPRANKS  ·  03-31
Tempest Therapeutics files to sell 8.27M shares of common stock for holders
Tempest Therapeutics Inc - Offers up to 8.27 Mln Shares of Common Stock for Resale by Selling Stockholders - SEC Filing
THOMSON REUTERS  ·  03-31
Tempest Therapeutics Inc - Offers up to 8.27 Mln Shares of Common Stock for Resale by Selling Stockholders - SEC Filing
BRIEF-Tempest Reports Year End 2025 Financial Results And Provides Business Update
Reuters  ·  03-30
BRIEF-Tempest Reports Year End 2025 Financial Results And Provides Business Update
Tempest Therapeutics Inc - Appoints Matt Angel as CEO and President
THOMSON REUTERS  ·  03-30
Tempest Therapeutics Inc - Appoints Matt Angel as CEO and President
Tempest Therapeutics Inc - Reports Net Loss of $26.3 Mln and Net Loss per Share of $6.33 for 2025
THOMSON REUTERS  ·  03-30
Tempest Therapeutics Inc - Reports Net Loss of $26.3 Mln and Net Loss per Share of $6.33 for 2025
Tempest Therapeutics Inc - Announces Positive Interim Data From Redeem-1 Phase 1/2a Trial of Tpst-2003
THOMSON REUTERS  ·  03-30
Tempest Therapeutics Inc - Announces Positive Interim Data From Redeem-1 Phase 1/2a Trial of Tpst-2003
Press Release: Tempest Reports Year End 2025 Financial Results and Provides Business Update
Dow Jones  ·  03-30
Press Release: Tempest Reports Year End 2025 Financial Results and Provides Business Update
Tempest FY25 net loss narrows to $26.3 million; cash drops to $7.7 million
Reuters  ·  03-30
Tempest FY25 net loss narrows to $26.3 million; cash drops to $7.7 million
Tempest Therapeutics CEO and President Matthew Angel acquires 231,482 common shares; value rises to $500,001
Reuters  ·  03-26
Tempest Therapeutics CEO and President Matthew Angel acquires 231,482 common shares; value rises to $500,001
Tempest Therapeutics announces USD 2 million private placement of 925,927 shares
Reuters  ·  03-23
Tempest Therapeutics announces USD 2 million private placement of 925,927 shares
Tempest Therapeutics Announces up to $6 Million Private Placement
THOMSON REUTERS  ·  03-23
Tempest Therapeutics Announces up to $6 Million Private Placement
Press Release: Tempest Therapeutics Announces Up To $6 Million Private Placement
Dow Jones  ·  03-23
Press Release: Tempest Therapeutics Announces Up To $6 Million Private Placement
Tempest Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview
Reuters  ·  03-23
Tempest Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview
Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support
Reuters  ·  03-11
Tempest Therapeutics selects Cincinnati Children’s AGCTC for TPST-2003 technology transfer and manufacturing support
Tempest Announces Partnership for Tpst-2003 in Preparation for Planned U.S. Registrational Study in 2026
THOMSON REUTERS  ·  03-11
Tempest Announces Partnership for Tpst-2003 in Preparation for Planned U.S. Registrational Study in 2026
Jakarta's Solution to Ease Burden on Bantargebang Landfill
Tempo  ·  03-11
Jakarta's Solution to Ease Burden on Bantargebang Landfill
Bantargebang Landfill Landslide Death Toll Rises to Five
Tempo  ·  03-10
Bantargebang Landfill Landslide Death Toll Rises to Five

Introduction

Company Name.
Tempest Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Issue price:
--